At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Teplizumab (drug)
- How long the study runs
- Study runs about 8 months (dates as stated)
- About the drug or intervention
- Teplizumab — drug: This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice.
- Patient visit burden
- Not specified by the sponsor
In plain English
This study looks at real-world information from people with type 1 diabetes who were treated with a medicine called teplizumab through Managed Access Programs (MAPs), which are ways for patients to get a medicine outside of normal approval routes. The study is funded by Sanofi. It uses data from people who have already received the treatment, rather than testing it on new patients.
Who can take part
- The patient (or parent, if under 18) gave written or electronic permission (consent) before any study activity, following local rules or an approved waiver.
- The patient received at least one day of teplizumab treatment as part of a Managed Access Program (MAP).
Who may not be able to
- The patient was taking part in another study that tests a treatment or procedure, starting that treatment or control on the index date. This means a study that asks patients to follow a plan that differs from normal care.
What taking part involves
- • Not stated — ask the trial team
Time commitment: Not stated — ask the trial team
Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.
- Type of study
- Observing health over time
- Ages
- Not specified
- Who
- All
- Number of participants
- 60
- Started
- 2026-03-16
- Last checked
- 2026-08
Plain English Summary
What is this study?
- • Testing a new treatment for type 1 diabetes
- • Clinical study - 60 participants
- • This study is a multi-country, multi-center retrospective observational cohort study based on secondary data collected via chart review, with the aim of describing patient characteristics (including relevant comorbidities), monitoring and treatment practices related to Type 1 diabetes mellitus (T1D) progression, and time to T1D progression in participants who received teplizumab as part of Managed Access Programs (MAPs)
Who can take part?
- • Adults
- • Diagnosed with type 1 diabetes
Where?
- • Birmingham - Investigational Site Number: 8260001
- • London - Investigational Site Number: 8260002
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
This study is a multi-country, multi-center retrospective observational cohort study based on secondary data collected via chart review, with the aim of describing patient characteristics (including relevant comorbidities), monitoring and treatment practices related to Type 1 diabetes mellitus (T1D) progression, and time to T1D progression in participants who received teplizumab as part of Managed Access Programs (MAPs). This study design was chosen in order to gain rapid insight into the current use of teplizumab in clinical practice and the characteristics of patients who received the treatment.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: Not specified
- Who can join: All genders
What the study is looking for
- ✓Patient written or electronic agreement to take part or assent (for patients \< 18 years old) according to local...
- ✓Patient received ≥ 1 day of teplizumab treatment as part of MAPs.
Who cannot take part
- ✗The above information is not intended to contain all considerations relevant to a patient's potential participation...
See the full criteria
Where Is This Study? (2 UK sites)
Investigational Site Number: 8260001
Birmingham B4 6NH, United Kingdom
Investigational Site Number: 8260002
London E1 1BB, United Kingdom
How to Get in Touch
Trial Transparency email recommended (Toll free for US & Canada)
Sponsor contactCONTACT